01 Multiplex Molecular Testing Expands Respiratory Virus Detection Influenza diagnostics are increasingly shifting toward multiplex molecular assays that can identify influenza alongside other respiratory pathogens from a single specimen. This approach helps clinicians distinguish influenza from infections with similar symptoms and can support treatment and infection-control decisions without requiring multiple separate tests. The expansion of multi-target molecular platforms is supporting influenza diagnostics market growth across hospitals, laboratories, and other clinical settings.For instance, in April 2025, the U.S. FDA cleared Roche Molecular Systems' cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test. The real-time RT-PCR assay simultaneously detects SARS-CoV-2, influenza A, influenza B, and RSV and is authorized for use with healthcare-collected respiratory specimens.
02 Home-Based Testing Broadens Access to Influenza Detection Influenza diagnostics are also moving closer to consumers as regulatory clearances expand the availability of tests that can be performed outside conventional laboratories and healthcare facilities. Home-based testing can allow individuals to identify influenza infection without an initial clinic visit, potentially supporting earlier decisions about seeking medical care or managing illness. This decentralization is shaping influenza diagnostics market trends toward more accessible testing options.For instance, in August 2025, the U.S. FDA granted 510(k) clearance to Wondfo USA's WELLlife Flu A&B Home Test. The anterior-nasal-swab test is designed for home detection of influenza A and B and received its FDA decision on August 20, 2025.
01 Expansion of Respiratory Testing Platforms Supports Faster Differential Diagnosis The need to distinguish influenza from other respiratory infections is encouraging healthcare providers to adopt platforms capable of testing multiple pathogens within a single workflow. Consolidating respiratory testing can reduce the need for separate assays and provide clinicians with broader diagnostic information from one specimen. This capability is strengthening influenza diagnostics market demand, particularly where rapid differentiation between respiratory viruses can influence clinical management.For instance, in February 2025, the FDA listed Abbott Molecular's Alinity m Resp-4-Plex among authorized respiratory molecular tests. The real-time RT-PCR platform simultaneously targets influenza A, influenza B, RSV, and SARS-CoV-2, illustrating the continued expansion of multi-analyte respiratory diagnostics.
01 Diagnostic Product Recalls Can Disrupt Testing Reliability Manufacturers must maintain consistent analytical performance across reagents, instruments, sample-collection components, and production lots. Quality problems can result in invalid results or product recalls, requiring laboratories to replace affected materials and potentially interrupt established testing workflows. Such events can increase operational costs and make healthcare providers more cautious when adopting diagnostic platforms.For instance, in April 2025, Abbott initiated a Class II recall of selected Alinity m Resp-4-Plex amplification kits. The FDA reported that the affected multiplex RT-PCR kits were subject to a recall involving testing for influenza A, influenza B, RSV, and SARS-CoV-2.
01 Expansion of At-Home Multiplex Respiratory Testing The development of home tests that identify several respiratory pathogens simultaneously creates opportunities for manufacturers to move influenza diagnostics into decentralized settings. Multiplex home testing can help consumers determine whether symptoms may be associated with influenza, COVID-19, or RSV while reducing dependence on separate tests. This creates influenza diagnostics market opportunities for companies developing easy-to-use respiratory testing platforms.For instance, in October 2025, the FDA granted 510(k) clearance to ACON Laboratories' Flowflex Plus RSV + Flu A/B + COVID Home Test. The multi-analyte antigen test is designed for home detection of RSV, influenza A/B, and SARS-CoV-2, expanding the range of respiratory pathogens that can be assessed through a single home test.
01 Maintaining Diagnostic Capability as Influenza Viruses Evolve Influenza diagnostics must remain capable of detecting circulating viruses as influenza viruses undergo genetic and antigenic changes. This creates an ongoing requirement for surveillance, assay evaluation, and validation against emerging strains. Diagnostic developers must therefore balance broad detection capability with sufficient specificity to identify clinically relevant influenza variants and distinguish them from other influenza A viruses.For instance, in March 2025, the FDA emphasized that most seasonal influenza tests may detect influenza A/H5N1 but that only tests specifically designed for subtyping can determine whether an individual has seasonal influenza A or influenza A/H5. The distinction highlights the continuing challenge of adapting diagnostic strategies for emerging influenza threats.
February 2026 Thermo Fisher Scientific expanded its respiratory diagnostic assay portfolio with new influenza detection kits designed for high-throughput laboratory testing. The products strengthen preparedness for seasonal influenza surveillance.
October 2025 QuidelOrtho expanded its respiratory diagnostics portfolio with advanced influenza and COVID-19 combination testing platforms. The systems improve laboratory efficiency and support comprehensive infectious disease screening.
August 2025 Abbott introduced upgraded rapid molecular influenza testing solutions with faster processing and improved sensitivity for point-of-care settings. The launch supports timely diagnosis and treatment of respiratory infections.
May 2025 Roche expanded its molecular diagnostics portfolio with enhanced multiplex PCR assays for the simultaneous detection of influenza A, influenza B, and other respiratory pathogens. The solutions improve diagnostic accuracy and turnaround time.